BACKGROUND: TNF-related apoptosis-inducing ligand (TRAIL) is considered as a tumor cell-specific cytotoxic agent. Through the aid of mesenchymal stem cells (MSCs), TRAIL is capable of inducing apoptosis of tumor cells in tumor sites. The present study was performed to investigate the cytotoxic effects of TRAIL-engineered MSCs on glioblastoma cells (C6) in vitro. MATERIALS AND METHODS: An expression vector of secreting form of TRAIL was used to engineer MSCs. The cytotoxic effects of TRAIL-transfected MSCs on C6 cells were invstigated using the MTT method and Hochest33258 staining after co-culture of the two cell types. RESULTS: TRAIL and control plasmid transfection of MSCs showed no significant effect on MSC's viability (p>0.05). A significant inhibition of C6 cells was observed when they were co-cultured with TRAIL-engineered MSCs (63.7%±0.12, p<0.05). CONCLUSION: Mesenchymal stem cells were very well tolerant to the transfection of TRAIL-bearing vectors. The cytotoxic effects of TRAIL-engineered MSCs on C6 cells indicates the therapeutic potential of this strategy for treatment of glioblastoma patients.
BACKGROUND:TNF-related apoptosis-inducing ligand (TRAIL) is considered as a tumor cell-specific cytotoxic agent. Through the aid of mesenchymal stem cells (MSCs), TRAIL is capable of inducing apoptosis of tumor cells in tumor sites. The present study was performed to investigate the cytotoxic effects of TRAIL-engineered MSCs on glioblastoma cells (C6) in vitro. MATERIALS AND METHODS: An expression vector of secreting form of TRAIL was used to engineer MSCs. The cytotoxic effects of TRAIL-transfected MSCs on C6 cells were invstigated using the MTT method and Hochest33258 staining after co-culture of the two cell types. RESULTS:TRAIL and control plasmid transfection of MSCs showed no significant effect on MSC's viability (p>0.05). A significant inhibition of C6 cells was observed when they were co-cultured with TRAIL-engineered MSCs (63.7%±0.12, p<0.05). CONCLUSION: Mesenchymal stem cells were very well tolerant to the transfection of TRAIL-bearing vectors. The cytotoxic effects of TRAIL-engineered MSCs on C6 cells indicates the therapeutic potential of this strategy for treatment of glioblastomapatients.
Authors: Antonella Mangraviti; Stephany Y Tzeng; David Gullotti; Kristen L Kozielski; Jennifer E Kim; Michael Seng; Sara Abbadi; Paula Schiapparelli; Rachel Sarabia-Estrada; Angelo Vescovi; Henry Brem; Alessandro Olivi; Betty Tyler; Jordan J Green; Alfredo Quinones-Hinojosa Journal: Biomaterials Date: 2016-05-21 Impact factor: 12.479
Authors: Hemn Mohammadpour; Ali Akbar Pourfathollah; Mahin Nikougoftar Zarif; Amir Ali Shahbazfar Journal: Sci Rep Date: 2016-06-22 Impact factor: 4.379
Authors: Xing Rong Guo; Qin Yong Hu; Ya Hong Yuan; Xiang Jun Tang; Zhuo Shun Yang; Dan Dan Zou; Liu Jiao Bian; Long Jun Dai; Dong Sheng Li Journal: Oncol Lett Date: 2016-03-01 Impact factor: 2.967